For ImmPact’s new CEO, Camarillo biotech company checked all the boxes
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
New CEO, new board chair, new funding for ImmPact Bio
Camarillo-based ImmPact Bio made multiple headlines with one announcement on Jan. 20: the a new CEO, a new board chair, and the closing of a $111 million Series B funding round. ImmPact, a biotechnology company developing cancer treatments based on chimeric antigen receptor (CAR) T-cell therapies, named Sumant Ramachandra as its new president and CEO. Read More →
With merger, ImmPact Bio plans growth and a move to LA
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Making an ImmPACT: New firm raises $18M to pursue T-cell therapies
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
